48 research outputs found
Effects of genotype on the response of Populus tremuloides michx. To ozone and nitrogen deposition
Elevated O 3 concentrations and N deposition levels co -occur in much of eastern United States. However, very little is known about their combined effects on tree growth. The effects of three O 3 treatments: charcoal-filtered air, non-filtered air and O 3 , added at the rate of 80 ppb for 6 hr d −1 3 d per week), four N deposition levels (0, 10, 20 and 40 kg ha −1 yr −1 ), and their interactions on growth of two Populus tremuloides clones in open-top chambers at two sites 600 km apart in Michigan were examined. Our results revealed a highly significant fertilization effect of the N treatments, even at the 10 kg ha −1 yr −1 rate. Ozone alone induced foliar injury, but not significant growth reductions. There was an indication that O 3 decreased growth at the O N level, but this decrease was reversed in all N treatments by the N fertilization effect. Further study is needed to more fully understand the combined effects of N deposition and O 3 .Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43906/1/11270_2004_Article_BF00480254.pd
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
This is the final version. Available on open access from Nature Research via the DOI in this recordData availability:
The study protocol including the statistical analysis plan is available at https://www.clarityibd.org/. Individual participant de-identified data that underlie the results reported in this article will be available immediately after publication for a period of 5 years. Due to the sensitive nature of the data, this will be made available to investigators whose proposed use of the data has been approved by an independent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to [email protected]. To gain access data requestors will need to sign a data access agreement. Data from the Virus Watch study is currently being archived on the Office of National Statistics Secure Research Service and will be available shortly. Source data are provided with this paper in the Source Data file. Source data are provided with this paper.Code availability:
Statistical analyses were undertaken in R 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria. Code has been made available at: https://github.com/exeteribd/clarityibd-public.Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations are lower and half-lives shorter in patients treated with infliximab than vedolizumab, following two doses of BNT162b2 (566.7 U/mL [6.2] vs 4555.3 U/mL [5.4], p <0.0001; 26.8 days [95% CI 26.2 - 27.5] vs 47.6 days [45.5 - 49.8], p <0.0001); similar results are also observed with ChAdOx1 nCoV-19 vaccination (184.7 U/mL [5.0] vs 784.0 U/mL [3.5], p <0.0001; 35.9 days [34.9 - 36.8] vs 58.0 days [55.0 - 61.3], p value < 0.0001). One fifth of patients fail to mount a T cell response in both treatment groups. Breakthrough SARS-CoV-2 infections are more frequent (5.8% (201/3441) vs 3.9% (66/1682), p = 0.0039) in patients treated with infliximab than vedolizumab, and the risk of breakthrough SARS-CoV-2 infection is predicted by peak anti-S RBD antibody concentration after two vaccine doses. Irrespective of the treatments, higher, more sustained antibody levels are observed in patients with a history of SARS-CoV-2 infection prior to vaccination. Our results thus suggest that adapted vaccination schedules may be required to induce immunity in at-risk, anti-TNF-treated patients
Recommended from our members
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn’s disease (ASTIClite): an open-label, multicentre, randomised controlled trial
Background
A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population.
Methods
This open-label, multicentre, randomised controlled trial was conducted in nine National Health Service hospital trusts across the UK. Adults (aged 18–60 years) with active Crohn's disease on endoscopy (Simplified Endoscopic Score for Crohn's Disease [SES-CD] ulcer sub-score of ≥2) refractory to two or more classes of biological therapy, with no perianal or intra-abdominal sepsis or clinically significant comorbidity, were recruited. Participants were centrally randomly assigned (2:1) to either HSCT with a reduced dose of cyclophosphamide (intervention group) or standard care (control group). Randomisation was stratified by trial site by use of random permuted blocks of size 3 and 6. Patients in the intervention group underwent stem-cell mobilisation (cyclophosphamide 1 g/m2 with granulocyte colony-stimulating factor (G-CSF) 5 μg/kg) and stem-cell harvest (minimum 2·0 × 106 CD34+ cells per kg), before conditioning (fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, and rabbit anti-thymocyte globulin [thymoglobulin] 7·5 mg/kg in total) and subsequent stem-cell reinfusion supported by G-CSF. Patients in the control group continued any available conventional, biological, or nutritional therapy. The primary outcome was absence of endoscopic ulceration (SES-CD ulcer sub-score of 0) without surgery or death at week 48, analysed in the intention-to-treat population by central reading. This trial is registered with the ISRCTN registry, 17160440.
Findings
Between Oct 18, 2018, and Nov 8, 2019, 49 patients were screened for eligibility, of whom 23 (47%) were randomly assigned: 13 (57%) to the intervention group and ten (43%) to the control group. In the intervention group, ten (77%) participants underwent HSCT and nine (69%) reached 48-week follow-up; in the control group, nine (90%) reached 48-week follow-up. The trial was halted in response to nine reported suspected unexpected serious adverse reactions in six (46%) patients in the intervention group, including renal failure due to proven thrombotic microangiopathy in three participants and one death due to pulmonary veno-occlusive disease. At week 48, absence of endoscopic ulceration without surgery or death was reported in three (43%) of seven participants in the intervention group and in none of six participants in the control group with available data. Serious adverse events were more frequent in the intervention group (38 in 13 [100%] patients) than in the control group (16 in four [40%] patients). A second patient in the intervention group died after week 48 of respiratory and renal failure.
Interpretation
Although HSCT with an immune-ablative regimen of reduced intensity decreased endoscopic disease activity, significant adverse events deem this regimen unsuitable for future clinical use in patients with refractory Crohn's disease.
Funding
Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research partnership
METAL-OXYGEN THERMOCHEMICAL BOND - DISSOCIATION ENTHALPIES FOR METAL PENTANE- 2,4-DIONATE COMPLEXES - A REVIEW
Design of a Decision Maker Agent for a Distributed Role Playing Game - Experience of the SimParc Project
International audienceThis paper addresses an ongoing experience in the design of an artificial agent taking decisions in a role playing game populated by human agents and by artificial agents. At first, we will present the context, an ongoing research project aimed at computer-based support for participatory management of protected areas (and more specifically national parks) in order to promote biodiversity conservation and social inclusion. Our applicative objective is, through a distributed role-playing game, to help various stakeholders (e.g., environmentalist, tourism operator) to collectively understand conflict dynamics for natural resources management and to explore negotiation management strategies for the management of parks. Our approach includes support for negotiation among players and insertion of various types of artificial agents (decision making agent, virtual players, assistant agents). In this paper, we will focus on the architecture of the decision making agent playing the role of the park manager, the rationales for its decision, and how it takes into account the preferences/votes from the stakeholders
Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial
The Sublimation Enthalpies of Metal Complexes of Pentane-2,4-Dione and Related Ligands - An Assessment Review
Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe
Establishment of a validated central reading system for ileocolonoscopy in an academic setting
The article is available via Open Access. Click on the 'Additional link' above to access the full-text.Published version, accepted version, submitted versio